CAGR: 10.1%Current Market Size: USD 400 MillionFastest Growing Region: APAC
Largest Market: North AmericaProjection Time: 2023-2030Base Year: 2022
The global custom antibody market is expected to grow from USD 400 million in 2022 to USD 863.6 million by 2030, at a CAGR of 10.1% during the Projection period 2023-2030. The growth of the custom antibody market is mainly driven by the rising R&D.
Antibodies are host proteins produced by the human body in response to the introduction of foreign bodies or foreign chemicals into the body. While these foreign chemicals or foreign bodies are known as antigens, they are recognized by an individual's immune system. Researchers from all over the world are conducting several sorts of studies that are focused on using the human body's natural function of producing antibodies in response to antigens representing specific illnesses or health conditions. The technique of creating these antibodies is simpler than that of conventional antibodies. As a result, the use of personalized antibodies in many sorts of research is increasing on a daily basis. In addition, a significant increase in biotechnology and pharmaceutical research activities is driving up demand for custom antibodies. Furthermore, the market for custom antibodies is expected to benefit from an increase in partnerships and collaborations between industry leaders and academic institutions. Government spending on healthcare infrastructure and medications is expanding. The advancement of R&D increased investment in the pharmaceutical business, and quick product innovation in the pharmaceutical department are all key aspects leading to the Market's growth.
Sample Request: - Global Custom Antibody Market
Market Dynamics:
Drivers:
The rising research efforts in the biology and life sciences industry, together with increased cooperation between academic institutes and industry leaders, are market growth factors. Patients' fast-expanding awareness of the efficacy of the medications is also contributing to market expansion. Furthermore, the increasing use of immunotherapy and targeted therapy due to their efficacy and low consequences is driving market expansion.
Restraints:
The market's restricting aspect is the increased emphasis on antibody alternatives for proteomic research. Furthermore, the high cost and time associated with identifying and developing viable antibodies impede market expansion. In addition, there is a lack of cancer awareness in developing and undeveloped economies. Because of limited financial resources and limited access to healthcare and other facilities, the majority of individuals go undiagnosed. During the Projection period, this issue is expected to impede the market growth.
Opportunities:
The manufacturer's increased focus on various antibodies for various health problem treatments is likely to provide opportunities for market expansion. Furthermore, growing pharmacy penetration, larger population adoption of healthcare insurance, the presence of modern healthcare facilities, and rising healthcare expenditure are all contributing to market expansion. Furthermore, increasing healthcare investments by government and industry leaders drive market growth.
Challenges:
The mAbs are very expensive. The poor financial capacities of the middle and low-income groups in emerging and undeveloped countries, as well as a lack of effective access to healthcare facilities, provide substantial challenges for market participants and may stymie market expansion.
Segmentation Analysis:
The global custom antibody market has been segmented based on research area, type, service, and region.
By Research Area
The research area segment is neurobiology, stem cells, infectious diseases, oncology, immunology, cardiovascular disease, and others. The oncology segment led the largest share of the custom antibody market with a market share of around 28.67% in 2022. Oncology is the most innovative therapy field in terms of clinical trial activity, the number of businesses investing in medicines, and the amount of money spent on these drugs all are contributing to the market expansion. Cancer is one of the leading causes of death, which has resulted in advances in cancer research and an increase in the proportion of therapeutic mAbs in research and clinical trials. This factor accounts for a sizable portion of the oncology market.
By Type
The type segment is polyclonal antibodies, recombinant antibodies, monoclonal antibodies, and others. The monoclonal antibodies segment led the largest share of the custom antibody market with a market share of around 42.34% in 2022. Due to significant R&D efforts by key industry players. Furthermore, the rising prevalence of lifestyle-related chronic diseases is expected to increase clinical urgency, fuelling the custom antibodies market throughout the Projection period. Custom monoclonal antibodies, on the other hand, are quite expensive, resulting in a greater cost of manufacture for end customers. As a result, the high production costs are anticipated to stifle segment expansion in the long run.
By Service
The service segment is antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development segment led the largest share of the custom antibody market with a market share of around 38.3% in 2022. Academic and research institutes, in-house research verticals of pharma and biotech firms, and CROs are among the service providers. For example, a report published in December 2022 stated that professionals from the University of Texas Health Science Center launched research on producing antibodies to heal brain damage and bone cancer. Both antibody therapies are in clinical studies as of December 2022. In addition, the institution signed a multimillion-dollar license arrangement with AlaMab Therapeutics Inc. The agreement involves unique antibodies manufactured by university researchers. As a result, increased collaboration between corporations and universities for antibody development is projected to drive market expansion.
Global Custom Antibody Market- Sales Analysis.
The sale of the custom antibody market expanded at a CAGR of 9.3% from 2016 to 2022.
Custom antibody services are the process of customizing antibodies for use in research and development. In recent years, there has been significant growth in the need for cutting-edge medical diagnostic techniques. This increase can be attributed to rising prevalence rates, a growing worry about public health issues among technology breakthroughs, a common populace that has permitted customized items with high-quality requirements, and an increase in healthcare spending. Hospitals employ custom antibody services to treat immune system disorders such as cancer and other maladies. Because of the faster diagnosis technique and shorter turnaround time, the operation of custom antibody services in healthcare centers is rising. Furthermore, because the exactness level is high, patients have extremely low chances of misdiagnosis.
Also, when compared to other diagnostic methods, it is a very cost-effective method for hospitals. Bioscience Research Centers employ custom antibody services to identify novel biomarkers. This helps researchers improve the quality of their study by exposing diseases at an early stage, while also lowering their reliance on commercial antibody services.
Thus, owing to the aforementioned factors, the global custom antibody market is expected to grow at a CAGR of 10.1% during the Projection period from 2023 to 2030.
By Regional Analysis:
The regions analyzed for the custom antibody market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America region dominated the custom antibody market and held a 37.9% share of the market revenue in 2022.
Global Custom Antibody Market - Country Analysis:
Germany's custom antibody market size was valued at USD 29 million in 2022 and is expected to reach USD 63.07 million by 2030, at a CAGR of 10.2% from 2023 to 2030. As a result of increased spending in drug research and development for the treatment of a wide range of ailments. Rising awareness for protein therapeutic antibody therapies, as well as the acceptance of personalized medicines, are important factors influencing the growth of the region's Custom Antibody Market.
China’s custom antibody market size was valued at USD 31.2 million in 2022 and is expected to reach USD 69.3 million by 2030, at a CAGR of 10.5% from 2023 to 2030. Because significant global businesses are increasingly interested in collecting regional revenue share by expanding into emerging regions. In addition, because of economic developments, global investors are increasingly investing in China. Regional companies are also expanding their presence in the global custom antibodies market.
India's custom antibody market size was valued at USD 24 million in 2022 and is expected to reach USD 52.9 million by 2030, at a CAGR of 10.4% from 2023 to 2030. India dominates the Asia Pacific custom antibody market. This is due to the presence of significant market participants and their participation in product development. Furthermore, there is a high demand for research, constantly changing illness profiles, increased government backing, and increasing funding activities, all of which contribute to the rise of biotechnology.
Key Industry Players Analysis:
To increase their market position in the global custom antibody market business, top companies focus on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, partnerships, joint ventures, etc.
Latest Development:
Report Metrics
Report Attribute |
Details |
Study Period |
2022-2030 |
Base year |
2022 |
CAGR (%) |
10.1% |
Market Size |
400 million in 2022 |
Projection period |
2023-2030 |
Projection unit |
Value (USD) |
Segments covered |
By Research Area, By Type, By Service, and By Region. |
Report Scope |
Revenue Projection, competitive landscape, company ranking, growth factors, and trends |
Companies covered |
Thermo Fisher Scientific Inc., Labcorp Drug Development, Creative Diagnostics, Abcam plc, YenZym Antibodies, LLC., Bio-Rad Laboratories, Inc, Kaneka Eurogentec S.A., Abmart, GenScript, and LifeSpan BioSciences, Inc. |
By Research Area |
|
By Type |
|
By Service |
|
Regional scope |
|
Scope of the Report
Global Custom Antibody Market By Research Area:
Global Custom Antibody Market By Type:
Global Custom Antibody Market By Service:
Global Custom Antibody Market By Region:
Global custom antibody market is expected to reach USD 863.6 million by 2030.
The custom antibody market is projected to have a CAGR of 10.1%.
Based on the type, the custom antibody market is segmented into polyclonal antibodies, recombinant antibodies, monoclonal antibodies, and others.
The rising research efforts in the biology and life sciences industry, together with increased cooperation between academic institutes and industry leaders, are market growth factors. Patients' fast-expanding awareness of the efficacy of the medications is also contributing to market expansion.
Based on the service, the global custom antibody market has been segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling.
Leading market players active in the global custom antibody market are Thermo Fisher Scientific Inc., Labcorp Drug Development, Creative Diagnostics, Abcam plc, YenZym Antibodies, LLC., Bio-Rad Laboratories, Inc, Kaneka Eurogentec S.A., Abmart, GenScript, LifeSpan BioSciences, Inc among others.
Political Factors- Pharmaceutical businesses in the United States are free to set their own prices for pharmaceuticals. This has prompted great anger in recent years, since many medication makers opt to offer their drugs at exorbitantly high costs. When these drugs, like as diabetes treatments, are critical to another person's survival, pricing them so expensive seems terribly unethical. As a result, governments are beginning to take an interest in controlling the prices at which pharmaceuticals can be sold. After all is said and done, this would imply that pharmaceutical corporations would make less profit.
Economic Factors- People's household income is increasing as their countries' economic conditions improve over time. It may allow them to obtain some necessary medications. People may feel compelled to purchase more expensive drugs that were previously out of reach for many people. Researchers are always working on medication modification, which leads to more useful and potentially advantageous drug production. As consumers purchase these drugs, the pharmaceutical industry thrives. Families' average healthcare expenditure is rising. When there are elderly members in a household, the likelihood of high healthcare costs increases. It also includes the cost of pharmaceuticals. It also allows pharmaceutical corporations to earn a higher profit even after adhering to government price limits.
Social Factors- Elderly people often have more serious health problems – and more of them – than younger people. As a result of the ageing population, we will face increasing health challenges. This increases demand for pharmaceutical products, resulting in increased revenue for the pharmaceutical sector. While poverty-related diseases such as malaria and AIDS have reduced significantly in recent years, diseases of affluence are becoming increasingly common. Obesity, while not a "disease," is a severe health issue in developed countries. Worse, obesity rates are rapidly increasing.
Technological Factors- The study of employing living creatures to better human lives in sectors such as agriculture, food science, and medicine is known as biotechnology. The role of biotechnology in medicine, in particular, may have an impact on the pharmaceutical sector. As new pharmaceuticals are developed from multiple biological sources, pharmaceutical corporations may be able to produce and market a broader range of drugs, generating greater money. On the other hand, if biotechnology is applied to create healthier food options, the pharmaceutical business may suffer. For example, several meat replacements derived from plants are being developed; because meat is thought to be a major source of health problems, this may minimise the need for pharmaceutical treatment of such diseases.
Environmental Factors- Because the production of pharmaceuticals has a high carbon footprint, many countries are enacting rules to reduce the environmental impact. Because complying with these requirements may be costly for fledgling businesses, they may fail to begin their operations. The manufacturing of pharmaceuticals produces a variety of biotechnology contaminants. These could be harmful to people's health. To ensure the safety of the people, the corporation must dispose of this garbage. Pharmaceutical firms, like other businesses, may take on some environmental responsibility. Companies might improve their image by donating money or running campaigns for environmental issues.
Legal Factors- Because pharmaceutical items are crucial, the government always adopts rules to combat fraud around expiration dates and drug production batches. If a corporation fails to follow the established criteria, it may risk legal action. Pharmaceutical businesses rely heavily on their databases. Customers may lose trust in them if they are harmed by cyber threats. It may also have an impact on their business. Pharmaceutical businesses should adhere to tight legal rules while developing the foundation for their operations and research. They ensure the product's safety. That assists them in avoiding legal complications. As a result, they can avoid the significant costs of legal processes.
List of Table
List of Figures